Caring for an ill or disabled family member imposes a well-documented burden on the caregiver. The benefits of a health intervention may be underestimated if “spillover” effects on family members are not captured, resulting in inaccurate conclusions of economic evaluations.
For the context of this special issue, family spillover is defined as the effect on an individuals’ quality of life due to having a family member with a chronic illness. We consider spillover to include family caregivers as well as non-caregivers. Extensions to larger social networks may also be included with justification (e.g., classmates for children’s illnesses).
Topics of interest include:
Applications: Measurement of spillover for specific conditions or populations of interest, inclusion of spillover in cost-effectiveness analyses.
Methods: Conceptual frameworks, measurement tools or approaches, methodological or practical issues in measurement; challenges to application in CEA.
Please submit an abstract describing your proposed paper by July 31, 2017 to the Editor, Chris Carswell . Full papers will be invited by August 31, 2017 and manuscripts due in early 2018.
AdisInsightThe recent first global approval of sarilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.
Representatives from our Adis BI team recently attended the Advances in Drug Discovery conference, which took place at The Wellcome Genome Campus Conference Centre in Cambridge on 6th and 7th March 2017.
The second in a two-part series of live webinars on Pharmacovigilance and Safety Biomarkers is set to take place on Tuesday, March 21, 2017.
Joining forces with Amplion, the leading biomarker business intelligence company, we aim to provide useful insights for anyone involved in R&D, product strategy decisions, or working directly in a drug safety related role.
The team behind AdisInsight are working in collaboration with their latest partners, Amplion, to host a special live webinar on December 13, 2016, on the topic “Pharmacovigilance and Safety Biomarkers”.
Safety biomarkers offer potential benefits throughout the drug lifecycle. These range from the identification of drug candidates most likely to be tolerated in humans, through to predictive identification of patients most likely to benefit from, or not be harmed by, a treatment.
The webinar will provide an introduction to biomarkers, their characteristics, and current uses in drug safety. Information presented will be of interest to those working in pharmaceutical/biotechnology industries and adjacent markets – including those working in R&D, making strategic decisions, or directly involved in drug safety.
Guest speakers for the session include Nitin Joshi, Editor of Drug Safety – the official journal of the International Society of Pharmacovigilance (ISoP), which is published by Adis.
Colleagues from SpringerNature recently took part in the 3rd Annual Risk Management and Pharmacovigilance summit in Vienna, with the following meeting report provided by Daniela Ranzani, Adis Business Intelligence Product Manager.
Traditional topics as well as best practice and case-study presentations remain at the core of the meeting, allowing attendees to share knowledge and diverse experiences. Regulation revisions were also discussed, with a spotlight on the GVP Modules V and IX updates. Attention to patients with dedicated programs was highlighted, and a presentation on social media listening reminded us all of the great power represented by such tools when used for PV, which also brings great challenges in terms of carefully managing this type of information. Continue reading “Meeting report: 3rd Annual Risk Management and Pharmacovigilance Summit, Vienna”→
Adis will join forces with new partners, Amplion, to deliver a series of expert webinars over the coming months. The first of these, taking place on October 25th 2016, will explore how top organisations manage clinical information and, in particular, biomarker information.
During this live webinar, you will learn:
Why biomarkers are important at different points of the healthcare value chain
How highly-effective companies manage their clinical information
How the collaboration between Adis and Amplion can help to move you up the biomarker intelligence maturity model
The webinar is free and open to all. Please register here.